OUTCOMES OF LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA CAUSED BY CHRONIC HEPATITIS B IN VIET DUC UNIVERSITY HOSPITAL

Việt Khải Ninh1, Hải Đăng Đỗ1, , Bảo Ngọc Ninh2, Quang Nghĩa Nguyễn1, Đức Hùng Dương1
1 Bệnh viện Hữu nghị Việt Đức
2 Trường Phổ thông Chuyên Sư phạm Hà Nội

Main Article Content

Abstract

Objectives: Evaluating the outcome of liver transplantation for hepatocellular carcinoma caused by hepatitis B at Viet Duc University hospital. Methods: The retrospective study of 48 patients with hepatocellular carcinoma (HCC) with hepatitis B performed liver transplantation at VietDuc University hospital from 5/2012 – 5/2022. Result: Average age 54.71 ± 8.41, pre-liver transplant adjuvant treatment with TACE or RFA accounted for 81.3%, 21.8% had pre - liver transplant alpha fetoprotein (AFP) > 200 ng/ml. Child-Pugh A 75%, within Milan criteria 39.6%. Living donor liver transplantation 18.8%, brain death donor liver transplantation 81.2%, cold ischemic time 167.6 ± 83.5 minutes. Hepatic thrombosis and portal vein thrombosis 4.2%, bleeding 4,2%, 90-day mortality 6.3%. The overall survival at 1 - year, 3 - year and 5 - year is 85.4%, 83.2 % và 83.2%. The disease - free survival at 1 – year, 3 – year and 5 – year 86.5%, 81.1% và 81.1%. Conclusion: Liver transplantation is an effective treatment for hepatocellular carcinoma due to hepatitis B.

Article Details

References

1. Kulik L and HB El-Serag. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019; 156(2):477-491 e1.
2. Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-699.
3. Yao FY, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33(6):1394-1403.
4. Mazzaferro V, et al., Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 2009; 10(1):35-43.
5. Nguyen VT. Hepatitis B infection in Vietnam: Current issues and future challenges. Asia Pac J Public Health. 2012; 24(2):361-373.
6. Majno PE, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997; 226(6):688-701; discussion 701-703.
7. Yao FY, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis. Hepatology. 2008; 48(3):819-827.
8. Sugawara Y, S Tamura, and M Makuuchi. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007; 25(4):310-312.
9. Lee SG, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008; 14(7):935-945.
10. Takada Y, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: A proposal of expanded criteria. Dig Dis. 2007; 25(4):299-302.
11. Mai Hồng Bàng, Lê Văn Thành, Vũ Văn Quang, Đào Tấn Lực, Lê Văn Lợi, Hồ Văn Linh, Vũ Ngọc Tuấn, Nguyễn Mạnh Dũng, Lê Trung Hiếu. Kết quả bước đầu ghép gan từ người hiến sống sử dụng mảnh ghép gan phải tại Bệnh viện Trung ương Quân đội 108. Tạp chí Y dược lâm sàng 108. 2021; 16(Số đặc biệt).
12. Lee N, KJ Kwon CH, Joh JW, Sinn DH, Lee JH, Gwak MS, Paik SW, Lee SK. Pre-transplant Predictors for 3-Month Mortality after Living Donor Liver Transplantation. J Korean Soc Transplant. 2014; 28(4):226-235.